TROP2-targeting chimeras (TRTACs) for tumor-selective membrane protein degradation and enhanced drug delivery
These findings establish TROP2 as a robust LTR and provide a versatile eTPD platform with profound translational potential for tumor treatment, as well as design TRTAC-drug conjugates, enabling targeted protein degradation together with enhanced drug delivery.